Kaori L. Fonseca

Kaori L. Fonseca

Auto-generated profile, based on publicly available information

Kaori L. Fonseca

Experimental TB Unit, Germans Trias I Pujol Research Institute (IGTP) , Badalona, Catalonia

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
17 August 2017 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
KFKaori L. Fonseca
Kaori L. Fonseca
PRPedro N. S. Rodrigues
Pedro N. S. Rodrigues
AOAnna Olsson
Anna Olsson
MSMargarida Saraiva
Margarida Saraiva
Tuberculosis (TB) is a devastating disease to mankind that has killed more people than any other infectious disease. Despite many efforts and successes from the scientific and health communities, the prospect of TB elimination remains distant. On the one hand, sustainable public health programs with affordable and broad implementation of anti-TB measures are needed. On the other hand, achieving TB elimination requires critical advances in three areas: vaccination, diagnosis, and treatment. It is also well accepted that succeeding in advancing these areas requires a deeper knowledge of host—pathogen interactions during infection, and for that, better experimental models are needed. Here, we review the potential and limitations of different experimental approaches used in TB research, focusing on animal and human-based cell culture models. We highlight the most recent advances in developing in vitro 3D models and introduce the potential of lung organoids as a new tool to study Mycobacterium tuberculosis infection. Tuberculosis (TB) is the number 1 killer in the world due to a bacterial infection. The study of this disease through clinical and epidemiological data and through the use of different experimental models has provided important knowledge on the role of the immune response generated during infection. This is critical for the development of novel vaccines and therapeutic strategies. However, in spite of the advances made, it is well accepted that better models are needed to study TB. This review discusses the different models used to study TB, highlighting the advantages and disadvantages of the available animal and cellular models and introducing recently developed state-of-the-art approaches based on human-based cell culture systems. These new advances are integrated in a road map for future study of TB, converging for the potential of lung organoids in TB research.

13 March 2020 in Mucosal Immunology
Verified
Journal Article
Open access
PDF file
KFKaori L. Fonseca
Kaori L. Fonseca
AMAna Raquel Maceiras
Ana Raquel Maceiras
RMRita Matos
Rita Matos
LSLuisa Simoes-Costa
Luisa Simoes-Costa
JSJeremy Sousa
Jeremy Sousa
MSMargarida Saraiva
Margarida Saraiva
Modulation of immunity and disease by glycans is increasingly recognized. However, how host glycosylation shapes and is shaped by tuberculosis remains poorly understood. We show that deficiency in the glucosaminyl (N-acetyl) transferase 1 (Gcnt1), a key enzyme for core-2 O-glycans biosynthesis, drives susceptibility to Mycobacterium tuberculosis infection. The increased susceptibility of Gcnt1 deficient mice was characterized by extensive lung immune pathology, mechanistically related to neutrophils. Uninfected Gcnt1 deficient mice presented bone marrow, blood and lung neutrophilia, which further increased with infection. Blood neutrophilia required Gcnt1 deficiency in the hematopoietic compartment, relating with enhanced granulopoiesis, but normal cellular egress from the bone marrow. Interestingly, for the blood neutrophilia to translate into susceptibility to M. tuberculosis infection, Gnct1 deficiency in the stroma was also necessary. Complete Gcnt1 deficiency associated with increased lung expression of the neutrophil chemoattractant CXCL2. Lastly, we demonstrate that the transcript levels of various glycosyltransferase-encoding genes were altered in whole blood of active tuberculosis patients and that sialyl Lewis x, a glycan widely present in human neutrophils, was detected in the lung of tuberculosis patients. Our findings reveal a previously unappreciated link between Gcnt1, neutrophilia and susceptibility to M. tuberculosis infection, uncovering new players balancing the immune response in tuberculosis.

29 May 2025 in medRxiv
Verified
Preprint
Open access
PDF file
KFKaori L. Fonseca
Kaori L. Fonseca
JFJudith Farrés
Judith Farrés
KBKetevan Barbakadze
Ketevan Barbakadze
IJIza Jikia
Iza Jikia
MTMalkhaz Tsotskhalashvili
Malkhaz Tsotskhalashvili
CVCris Vilaplana
Cris Vilaplana
Background: Drug-resistant tuberculosis (TB) remains a formidable global health challenge. Host-directed therapies (HDTs) offer the potential to mitigate tissue damage, reduce treatment duration, and improve clinical outcomes by modulating immune responses. We assessed the safety and potential efficacy of adjunctive ibuprofen—an inexpensive, well-tolerated non-steroidal anti-inflammatory drug—in patients with pre-extensively drug-resistant (pre-XDR) and extensively drug-resistant (XDR) TB. Methods: In this prospective, open-label, randomized pilot study ( NCT02781909 ) conducted in Georgia, 28 adults with bacteriologically confirmed pulmonary pre-XDR or XDR-TB were randomized 1:1 to receive either standard-of-care (SoC) TB treatment alone (n=14) or SoC plus 400 mg ibuprofen daily during the first 2 months (n=14). Participants were followed for 6 months. The primary endpoints were early sputum culture conversion and radiological improvement. Secondary endpoints included WHO-defined final treatment outcomes, safety, health-related quality of life (HQoL), and changes in inflammatory markers. Findings: By week 2, culture negativity was achieved in 27% of control participants versus 9% in the ibuprofen group (risk difference 18%, 95% CI −13 to 50). The median time to culture conversion was 4 months in both groups. At month 2, favourable X-ray evolution was observed in 64% of controls compared with 54% of the ibuprofen group (risk difference 9%, 95% CI −32 to 50), with 90% of participants in each group showing improvement by month 6. Final treatment outcomes were comparable (≈71% cured) and the incidence of safety-related events did not differ significantly. Notably, the ibuprofen group exhibited greater proportional reductions in inflammatory markers—including a statistically significant decrease in the monocyte-to-lymphocyte ratio at months 2 and 5, along with reductions in interferon gamma levels and the enrichment score for Thompson_FAIL_13 gene signature at month 6. Interpretation: Although adjunctive ibuprofen did not improve primary microbiological or radiological endpoints, its excellent safety profile and significant anti-inflammatory effects support its potential role as an immune-modulating adjunct in the treatment of drug-resistant TB. These findings warrant further investigation in larger studies to optimize dosing and evaluate clinical benefits. Funding: Catalan Government (2021 SGR 00920), Spanish Government-FEDER Funds (CPII18/00031, PI20/01424 and CB06/06/0031, and European Union’s Horizon 2020 research and innovation program under grant agreement No. 847762 (SMA-TB project). Research in context: Evidence before this study: Drug-resistant tuberculosis (TB) remains a major global health challenge. Host-directed therapies (HDTs) have emerged as a means to shorten treatment, improve outcomes and limit tissue damage from excessive inflammation. In preclinical models of active TB, non-steroidal anti-inflammatory drugs (NSAIDs) enhanced bacterial control and reduced lung pathology. Clinical data on NSAIDs as HDTs are scarce, confined to small studies in tuberculous meningitis and TB patients with diabetes, which reported encouraging but preliminary benefits. Added value of this study: This is the first randomized trial of adjunctive ibuprofen in patients with pre-XDR and XDR-TB. Whilst ibuprofen did not confer microbiological or clinical benefit at two and six months, it was safe, well tolerated and significantly lowered systemic inflammatory markers. Baseline imbalances in disease severity and high inter-patient variability likely obscured any clinical effect despite reduced inflammation. Implications of all the available evidence: Our findings demonstrate that ibuprofen is a safe adjunct in drug-resistant TB and can mitigate harmful inflammation. Future work should explore optimised dosing regimens, alternative HDT candidates and more sensitive or tailored endpoints—potentially focusing on patient subgroups most likely to benefit. Such refinements will be essential to reveal the true clinical value of HDTs across diverse TB populations.

30 September 2011 in Current Opinion in Biotechnology
Verified
Journal Article
Closed access
Marco F. L. LemosMarco F. L. Lemos
Marco F. L. Lemos
ILIllyane S.M. Lima
Illyane S.M. Lima
KFKaori L. da Fonseca
Kaori L. da Fonseca
Hugo MonteiroHugo Monteiro
Hugo Monteiro
Ana Cristina EstevesAna Cristina Esteves
Ana Cristina Esteves

2 December 2025 in medRxiv
Verified
Preprint
Open access
PDF file
LALilibeth Arias
Lilibeth Arias
ZWZiyaad Waja
Ziyaad Waja
Nestani TukvadzeNestani Tukvadze
Nestani Tukvadze
TMTumelo Moloantoa
Tumelo Moloantoa
KOKennedy Otwombe
Kennedy Otwombe
CVCris Vilaplana
Cris Vilaplana
Background: As novel strategies are needed to improve tuberculosis (TB) outcomes and shorten treatment; we evaluated whether host-directed therapy with non-steroidal anti-inflammatory drugs (NSAIDs) could enhance treatment response when added to standard therapy. Methods: We conducted a phase 2b, double-blind, placebo-controlled, randomized trial in South Africa and Georgia. Adults with microbiologically confirmed pulmonary TB were randomized to receive standard therapy plus acetylsalicylic acid (ASA) (300 mg), ibuprofen (IBU) (400 mg), or placebo twice daily for 4 weeks and once daily for 4 weeks. Primary end points were time to a 67% reduction in the clinical symptom/sign-based TB score (TBS) and time to stable sputum culture conversion (SCC). Safety and clinical, radiological and microbiological assessments were performed up to 24 weeks after treatment completion. Results: Of 221 randomized participants, 204 were included in the analysis. No significant differences were observed in the primary end points; median time to 67% TBS reduction was 4.5 weeks (ASA) and 5.0 weeks (IBU and placebo), and median time to stable SCC was 8 weeks in all groups. Both NSAIDs were associated with earlier cavity resolution at week 8, sustained at week 24 for ASA. IBU was associated with greater clinical improvement in multidrug-resistant-TB. Adverse event rates were similar across arms. Conclusions: Adjunctive ASA and IBU did not shorten the time to clinical or microbiologic response but were associated with earlier cavity resolution and improved TBS in specific subgroups, with similar safety to standard therapy alone. Funded by the European Union’s Horizon 2020; ClinicalTrials.gov number, NCT04575519 .

13 March 2026 in medRxiv
Verified
Preprint
Open access
PDF file
JGJuan M. Garcia-Illarramendi
Juan M. Garcia-Illarramendi
CSChiara Sopegno
Chiara Sopegno
KFKaori L. Fonseca
Kaori L. Fonseca
LALilibeth Arias
Lilibeth Arias
KBKetevan Barbakadze
Ketevan Barbakadze
CVCris Vilaplana
Cris Vilaplana
Background: In extensively drug-resistant and pre–extensively drug-resistant TB, bacteriology-based monitoring often fails to capture structural lung recovery and patient-reported functional health. We aimed to characterize multidomain treatment response and examine host inflammatory and transcriptional features associated with incomplete recovery. Methods: We conducted an ancillary analysis of a prospective, open-label, pilot study evaluating adjunctive ibuprofen in XDR-TB ( NCT02781909 ). Participants were assessed at baseline and during treatment using TBS, chest radiography, sputum culture, SGRQ, blood cell indices, plasma cytokines, and whole-blood transcriptomic profiling. Clinical and laboratory measures were compared across outcome groups, and blood transcriptional profiles were analyzed in relation to treatment outcomes. Results: Here we show that microbiological and symptomatic improvement occurred earlier than radiological and functional recovery. Higher baseline systemic inflammation, including elevated NLR, SII, and IL-6, as well as increased expression of interferon-related genes such as CD274 and GBP5 , were associated with poorer radiological and SGRQ outcomes at 6 months. In contrast, transient elevations of IL-8 and IL-4 were associated with early bacteriological clearance. IL-8 was the only plasma biomarker consistently correlated with symptom severity, radiological findings, and functional health. Conclusions: Treatment response in drug-resistant TB is asynchronous across biological domains. Integrated host profiling identifies inflammatory and transcriptional features associated with incomplete structural and functional recovery, supporting the use of multidimensional endpoints to better capture long-term outcomes and inform individualized patient management. Plain Language Summary: People with highly drug-resistant tuberculosis can clear the infection but still experience lung damage and reduced quality of life after treatment. In this study, we examined recovery using several measures, including symptoms, chest X-rays, blood markers of inflammation, and gene activity, in addition to tests for tuberculosis bacteria. We analyzed data and stored samples from a small clinical trial to see how these measures changed over time. We found that lung structure and quality of life improved more slowly than bacterial clearance. People with higher levels of inflammation before treatment were more likely to have ongoing lung changes and poorer quality of life later. These results suggest that tuberculosis care should look beyond bacterial clearance and include monitoring inflammation to better support long-term recovery.